BTW why did GILD drop their partnership with Achillion?
The GILD/ACHN partnership was not for ACH-1625, but was for ACH-1095, an NS4A antagonist (separate drug and separate HCV drug class), and ended due to GILD's concerns with pre-clinical cardiac tox signals. ACHN hopes to take ACH-1095 into Phase 1 on its own early next year; if that initial data is good, GILD has an option to opt back into the program.
Market Data 
Markets 
AI
